arrow
P

Peter M. Voorhees

atrium health
H指数:49
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Receiving Teclistamab: A Panel Chart Review Study

真实世界中接受teclistamab治疗的复发或难治性多发性骨髓瘤患者的患者特征、治疗模式及临床结局:一项专家图表回顾研究

2026-03-260
OAAI
Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myeloma

Belantamab mafodotin、carfilzomib、lenalidomide和dexamethasone用于复发或难治性多发性骨髓瘤

2026-02-240
OAAI
The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience

外周髓外和骨旁浆细胞瘤对使用teclistamab治疗的多发性骨髓瘤患者治疗结局的影响:美国骨髓瘤免疫治疗联盟真实世界经验

2025-11-280
OAAI
Outcomes of CAR T-Cell therapy in relapsed/refractory multiple myeloma by race: a multicenter real-world study

CAR T细胞疗法在复发/难治性多发性骨髓瘤中的疗效:一项多中心真实世界研究

2025-11-210
OAAI
Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses

达鲁单抗联合来那度胺维持治疗在新诊断的多发性骨髓瘤移植后的亚组分析

2025-10-060
OA
Accurate recognition and characterization of biclonal gammopathies by mass spectrometry
2025-10-010
PRE
Safety and Efficacy of BCMA directed Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Plasma Cell Leukemia

BCMA定向嵌合抗原受体T细胞疗法治疗浆细胞白血病的有效性与安全性

2025-09-010
OAAI
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium

接受过BCMA靶向疗法的复发/难治性多发性骨髓瘤患者中teclistamab的治疗效果:一项来自美国多发性骨髓瘤免疫治疗联盟的多中心研究

2025-06-250
OAAI
Plasma Proteomic Profiles Among White and African American Individuals With Monoclonal Gammopathy of Unknown Significance (MGUS) and Multiple Myeloma (MM)

血浆蛋白质组学特征:白人与非裔美国人中意义未明单克隆丙种球蛋白血症(MGUS)和多发性骨髓瘤(MM)患者的比较

2025-06-140
PRE
Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the US Multiple Myeloma Immunotherapy Consortium

复发难治性多发性骨髓瘤(RRMM)老年患者接受teclistamab治疗后的结局:一项来自美国多发性骨髓瘤免疫治疗联盟的多中心研究

2025-05-090
OA
Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at 2 Institutes

干细胞动员量与达鲁单抗(Dara)和来那度胺(Len)含药四联诱导疗法在 newly diagnosed multiple myeloma(NDMM)患者中的应用:2家机构真实世界经验

2025-04-110
PRE
Nivolumab As an Adjunctive Therapy in Relapsed Refractory Multiple Myeloma Patients with Sub-Optimal Response to Idecabtagene Vicleucel

纳武利尤单抗作为伊达木单抗偶联物治疗疗效欠佳的复发难治性多发性骨髓瘤患者的辅助治疗

BLOOD
IF23.1
2024-11-050
PRE
Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at Two Institutes

干细胞动员量与达雷妥尤单抗(Dara)和来那度胺(Len)联合的四药联合诱导疗法在 newly diagnosed multiple myeloma(NDMM)患者中的真实世界经验:一项来自两家机构的观察研究

BLOOD
IF23.1
2024-11-050
PRE
Efficacy of Stem Cell Boost (SCB) for Chimeric Antigen Receptor T Cell (CAR-T)-Related Hematologic Toxicity in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)- a Multi-Center Real World Experience

干细胞增强(SCB)对嵌合抗原受体T细胞(CAR-T)相关血液学毒性的疗效:一项多中心真实世界研究经验(针对复发/难治性多发性骨髓瘤患者)

BLOOD
IF23.1
2024-11-050
PRE
A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma
2024-10-250
OAAI
Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma

多发性骨髓瘤嵌合抗原受体T细胞治疗后免疫效应细胞相关性小肠结肠炎

2024-10-160
OAAI